Funding for this research was provided by:
National Heart, Lung, and Blood Institute (T32HL007208)
National Institutes of Health Center for Multi- and Trans-ethnic Mapping of Mendelian and Complex Diseases (5U01HG009080)
National Human Genome Research Institute (1K08HG010155, 5R01HG01014002)
Massachusetts General Hospital
Received: 19 May 2020
Accepted: 22 June 2020
First Online: 6 July 2020
Ethics approval and consent to participate
: Work was performed under UK Biobank application #7089. Informed consent was obtained electronically at the time of study enrollment. Data analysis was approved by the Partners Healthcare institutional review board.
: Not applicable.
: A.V.K. has served as a consultant to Sanofi, Medicines Company, Amgen, Maze Pharmaceuticals, Navitor Pharmaceuticals, and Color Genomics; received speaking fees from Illumina, the Novartis Institute for Biomedical Research; received sponsored research agreements from the Novartis Institute for Biomedical Research and IBM Research, and reports a patent related to a genetic risk predictor (20190017119). The remaining authors have no disclosures.